1) Stallmach A, et al. IBD and CDI: The contrasting views of different clinical
professionals. Abstract presented at ECCMID 2016.
2) Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in
Europe: a hospital-based survey. Lancet. 2011;377:63-73.
3) Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J
Infect. 2013; 66(2):115-28.
4) Wilcox MH, et al. Financial burden of hospital-acquired Clostridium difficile
infection. J Hosp Infect. 1996;34:23-30.10.
5) Dubberke ER, et al. Review of a current literature on the economic burden of
Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30:57-66.
6) Magalini S, et al. An economic evaluation of Clostridium difficile infection
management in an Italian hospital environment. Eur Rev Med Pharmacol Sci.
2012;16:2136-41.
7) Jen, MH, et al. Increased health burden associated with Clostridium difficile
diarrhoea in patients with inflammatory bowel disease. Alimentary pharmacology &
therapeutics. 33.12 (2011): 1322-1331.
8) Aguado, JM, et al. Highlighting clinical needs in Clostridium difficile infection: the
views of European healthcare professionals at the front line. Journal of Hospital
Infection. 90.2 (2015): 117-125.
9) McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings
and advances in therapy. Pharmacotherapy. 2007;27:1029-39.1.
10) Sunenshine R, McDonald L. Clostridium difficile-associated disease: new challenges
from an established pathogen. Cleve Clin J Med. 2006;73:187-97.
11) Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and
management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.
12) European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of
healthcare-associated infections and antimicrobial use in European acute care
hospitals 2011-2012. Stockholm, 2013. Available from:
http://ecdc.europa.eu/en/publications/Pu...
(last accessed April 2016).
13) European Centre for Disease Prevention and Control/European Medicines Agency
(ECDC/EMEA). Joint technical report The bacterial challenge: time to react. Stockholm:
ECDC / EMEA; 2009. Available from:
http://ecdc.europa.eu/en/publications/Pu...
(last accessed April 2016).
14) Oake N, et al. The effect of hospital-acquired Clostridium difficile infection on
in-hospital mortality. Arch Intern Med. 2010;170:1804-10.
15) Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients
with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis.
2013;56:1108-16.
16) Bauer MP, et al. European Society of Clinical Microbiology and Infectious Disease
(ESCMID): treatment guidance document for Clostridium difficile-infection (CDI). Clin
Micro Infect. 2009;15:1067-79.
17) Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin and
metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Micro
Infect. 2008;14(Suppl 7):S103-4.
18) Lowy I, et al. Treatment with monoclonal antibodies against Clostridium difficile
toxins. N Engl J Med. 2010;362;3:197-205.
19) Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N
Engl J Med. 2011;364:422-31.
CONTACT: For further information please contact: Donna Wright, Ruder Finn,dwright@ruderfinn.co.uk, Tel: +44(0)20-7438-3085; Julie Henderson, AstellasPharma EMEA, julie.henderson@astellas.com, Tel: +44(0)7786-171-214
